Orchid Pharma Ltd
Orchid Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
2 of 3 strong
The short version
For FY '27, Orchid Pharma targets sales growth of 10% to 15%, aiming to return to pre-abrerration growth trends. Targeted sales growth for FY '27 is in the range of 10% to 15%, aiming to resume pre-abrerration growth trends.
From Orchid Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- For FY '27, Orchid Pharma targets sales growth of 10% to 15%, aiming to return to pre-abrerration growth trends.
- Growth is expected primarily from non-regulated markets, especially Africa and Southern Asia, with continued competitiveness in Cephalosporin.
- The company remains cautious due to dynamic industry pricing influenced by geopolitical factors but sees early signs of price stabilization.
- The 7ACA project is on track for Q1 CY 2027 commercial commissioning, expected to support growth.
- Expansion via the merger with Dhanuka Laboratories is anticipated to improve operational efficiencies and enhance revenue streams.
2 more points from Orchid Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Orchid Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Downstream Capex Addition: Planned for downstream products related to 7ACA to enhance capacity with high asset turn; aimed at about 5% additional EBITDA contribution. Current focus on reengineering existing plants to minimize investment. (Page 12)
- Fill-Finish Facility for Cefiderocol: Capex estimated around INR 50 crores including equipment, capability, and filing dossier; part of the Cefiderocol project with moderate investment planned. (Page 7)
- 7ACA Project: Commissioning targeted in Q1 CY 2027; ongoing optimization and validation of process technology for stable commercial production. (Page 4)
- Sterile FDA Platform: To be operational with fill-finish and formulation facilities enabling integrated sterile Cephalosporin manufacturing and commercialization. (Page 5)
2 more points from Orchid Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Orchid Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Orchid Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Orchid Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹304 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Orchid Pharma Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Orchid Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Orchid Pharma Ltd Q4 FY26 results?
For FY '27, Orchid Pharma targets sales growth of 10% to 15%, aiming to return to pre-abrerration growth trends. Targeted sales growth for FY '27 is in the range of 10% to 15%, aiming to resume pre-abrerration growth trends.
What is Orchid Pharma Ltd share price analysis?
Orchid Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 348.0 with a market cap of ₹9,439 Cr. Investors should review the full earnings analysis for detailed insights.
Is Orchid Pharma Ltd planning capital expenditure?
Downstream Capex Addition: Planned for downstream products related to 7ACA to enhance capacity with high asset turn; aimed at about 5% additional EBITDA contribution.
Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.